Company profile
Cardiovascular Disease Biomarkers | United Kingdom | PlaqueTec
PlaqueTec is pioneering the development of biomarker-based, cardiovascular personalised medicine strategies, using its novel Liquid Biopsy System, to transform the prevention, diagnosis and treatment of Coronary Artery Disease - the leading cause of death worldwide.
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jun 2019 to 31 Aug 2020
"PlaqueTec has an advanced medical catheter that can detect biological signalling directly at the site of coronary artery disease. In clinical use it has shown that intracoronary biomarkers (i) differ depending on the state of disease ii) differ from patient to patient and iii) differ to systemic biomarker levels (i.e. those detected in standard blood sam...
1 Jan 2018 to 31 Oct 2018
"The lead applicant has developed a high performance catheter that a doctor can use to take blood samples from deep within the heart at the site of diseased heart tissue. Crucially, by collecting the blood at the site of the diseased tissue, the doctor can detect blood samples that are known to be exclusively associated with the disease. This close associ...
1 Mar 2016 to 31 Dec 2016
Proof of Concept application for R&D on the design and manufacture of a novel, intra-arterial catheter used to sample biomarkers associated with coronary artery disease (CAD). Initial clinical studies with the device have uniquely shown that high concentrations of biomarkers exist at sites of CAD. These biomarkers allow biological processes underlying the...
